Dr Steven Petratos des- cribes his research |
MS is commonly induced by the specific destruction of the protective sheath of nerve fibres, known as myelin, by immune cells, which mistakenly attack this structure in the brain. Inevitably, this leaves the nerve fibres bare and susceptible to further damage with severe and permanent implications for patients suffering with this devastating disease. Importantly, the molecules which may contribute to the replenishment of the myelin-forming cells, or oligodendrocytes, are poorly understood.
Using specialized human stem cells, we plan to show the relevance of an important protein that can regulate the growth of cells called oligodendrocytes. These cells are crucial in multiple sclerosis because they create the myelin sheath. Dr Petratos and his team are identifying how one particular protein helps transport a hormone involved in cell metabolism (thyroid hormone) and how it affects the oligodendrocytes. Findings from this study may allow for future work that targets these stem cells of the brain to enhance their repair of nerve fibres subsequent to MS 'attack'. Repair of these nerve fibres may prevent further clinical progression of MS enhancing the quality of life for all sufferers.
“My research focuses on the progressive forms of MS,” said Steven. “Our recent landmark research showed that a specific molecule within nerve fibres is altered or damaged, and that can lead to the progressive form of MS.” Using direct gene therapy, Steven and his team discovered they can block the molecule and subsequently put a handbrake on the progressive form of MS.
“Our new approach to treating MS patients with the progressive forms of the disease is by using their own stem cells", added Steven. “This limits further progression of the disease and ultimately leads to a better quality of life for patients.”
Video link: youtu.be/oYaZYLrCukA
No comments:
Post a Comment
Thankyou for your comment. We moderate all messages and may take a little time to review your comment. Please email inquiries to ccs.comms@monash.edu.